Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

En+ Group is studying the possibility of building a gas plant near the Kovykta field

3/2/23 ENPG

Gazprom Nedra will build an LNG plant in Krasnoyarsk Krai

3/2/23 GAZP

Rusal invests ₽7 billion in aluminum discs and wide profile production

3/2/23 RUAL

GAZ Group plans to produce up to 300 electric buses in 2023

3/2/23 GAZA

The Altria Group announced a quarterly dividend

3/2/23 MO

Yandex released an expanded version of the browser for business

3/2/23 YNDX

RusHydro plans to increase the number of electric filling stations to 1,500 by 2035

3/2/23 HYDR

Sberbank launched acquiring for stores in the Crimea and Sevastopol

3/2/23 SBER

MTS gradually shuts down 3G networks, freeing up frequencies for 4G

3/2/23 MTSS

Felix Evtushenkov assessed prospects of Binnopharm Group's IPO

3/2/23 AFKS